{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:09:24Z","timestamp":1794863364960,"version":"4.9.1"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.parkreldis.2022.03.012","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T21:43:53Z","timestamp":1647899033000},"page":"68-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Foslevodopa\/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum"],"prefix":"10.1016","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8333-7738","authenticated-orcid":false,"given":"Matthew","family":"Rosebraugh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7986-4447","authenticated-orcid":false,"given":"Sven","family":"Stodtmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4444-1230","authenticated-orcid":false,"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio F.","family":"Facheris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9996","key":"10.1016\/j.parkreldis.2022.03.012_bib1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.parkreldis.2022.03.012_bib2","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.parkreldis.2022.03.012_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2165\/11310940-000000000-00000","article-title":"Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease","volume":"24","author":"Antonini","year":"2010","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.parkreldis.2022.03.012_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","article-title":"Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study","volume":"13","author":"Olanow","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.parkreldis.2022.03.012_bib5","series-title":"Foslevodopa\/foscarbidopa: a New Subcutaneous Treatment for Parkinson's Disease","author":"Rosebraugh","year":"2021"},{"key":"10.1016\/j.parkreldis.2022.03.012_bib6","doi-asserted-by":"crossref","DOI":"10.3233\/JPD-161042","article-title":"Levodopa-carbidopa intestinal gel pharmacokinetics: lower variability than oral levodopa-carbidopa","author":"Othman","year":"2017","journal-title":"J. Parkinsons Dis."},{"issue":"2","key":"10.1016\/j.parkreldis.2022.03.012_bib7","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1208\/s12248-012-9439-1","article-title":"Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients","volume":"15","author":"Nyholm","year":"2013","journal-title":"AAPS J."},{"issue":"4","key":"10.1016\/j.parkreldis.2022.03.012_bib8","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3233\/JPD-212813","article-title":"Foslevodopa\/foscarbidopa is well tolerated and maintains stable levodopa and carbidopa exposure following subcutaneous infusion","volume":"11","author":"Rosebraugh","year":"2021","journal-title":"J. Parkinsons Dis."},{"issue":"11 Suppl 2","key":"10.1016\/j.parkreldis.2022.03.012_bib9","first-page":"25","article-title":"Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies","volume":"39","author":"Yeh","year":"1989","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.parkreldis.2022.03.012_bib10","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/mds.23861","article-title":"Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease","volume":"26","author":"Hauser","year":"2011","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.parkreldis.2022.03.012_bib11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1056\/NEJM198402233100802","article-title":"The \"on-off\" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport","volume":"310","author":"Nutt","year":"1984","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.parkreldis.2022.03.012_bib12","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2125.1986.tb02913.x","article-title":"The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations","volume":"22","author":"Hardie","year":"1986","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.parkreldis.2022.03.012_bib13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ana.410180505","article-title":"The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism","volume":"18","author":"Nutt","year":"1985","journal-title":"Ann. Neurol."},{"issue":"9","key":"10.1016\/j.parkreldis.2022.03.012_bib14","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.parkreldis.2015.06.012","article-title":"Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations","volume":"21","author":"Trenkwalder","year":"2015","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2022.03.012_bib15","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/bs.irn.2017.03.001","article-title":"Device-aided treatment strategies in advanced Parkinson's disease","volume":"132","author":"Timpka","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"issue":"9","key":"10.1016\/j.parkreldis.2022.03.012_bib16","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1080\/03007995.2021.1953971","article-title":"Epidemiology of skin event rates among users of pumps for the subcutaneous administration of drugs for chronic conditions","volume":"37","author":"Jick","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"issue":"6","key":"10.1016\/j.parkreldis.2022.03.012_bib17","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00592-015-0784-2","article-title":"Clinical review: insulin pump-associated adverse events in adults and children","volume":"52","author":"Ross","year":"2015","journal-title":"Acta Diabetol."},{"issue":"11","key":"10.1016\/j.parkreldis.2022.03.012_bib18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2165\/00002512-200421110-00001","article-title":"Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease","volume":"21","author":"Deleu","year":"2004","journal-title":"Drugs Aging"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802022000797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802022000797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:25:08Z","timestamp":1761179108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802022000797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":18,"alternative-id":["S1353802022000797"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2022.03.012","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Foslevodopa\/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2022.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}